Testing a new RSV vaccine for safety and immune response
Part of Immune system & allergy, Infections, Lungs & breathing clinical trials.
This trial tests a new RSV vaccine in two phases. First, it will be given to healthy adults 18 and older to check safety. Then, it will be studied in adults 50 and older, including those with stable health conditions, to see if it helps protect against RSV, a common virus that can cause serious breathing problems in older people.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old (for Phase I) or 50 years old (for Phase II).
- You are generally healthy or have a stable long-term health condition (like controlled high blood pressure).
- You are not pregnant, breastfeeding, or planning to become pregnant during the study; you agree to use birth control for 6 months after the vaccine.
- You have not received an RSV vaccine or had a known RSV infection in the past year.
- You do not have a weakened immune system from a condition like HIV, lupus, or taking high-dose steroids recently.
- You have not used any other experimental vaccine or product in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called AK0529 for babies and toddlers hospitalized with RSV. It aims to see if the drug helps them recover faster and is safe for this age group.
This trial tests an experimental vaccine for respiratory syncytial virus (RSV), a common virus that can cause serious lung infections, especially in older adults. The study checks if the vaccine is safe and how the body responds to it.
This study tests a new vaccine to protect against RSV (a common respiratory virus that causes cold-like illness, especially serious in older adults). The vaccine is made in laboratory cell cultures and includes an immune-boosting ingredient. Researchers want to see if it's safe and if it helps your body fight RSV infection.
This trial tests a new vaccine against respiratory syncytial virus (RSV), a common virus that can cause lung infections. It is for healthy adults aged 18 and older, to see if the vaccine is safe and produces a good immune response.
This trial tests an experimental vaccine to protect older adults against respiratory syncytial virus (RSV), a common virus that can cause serious lung infections. It looks at whether the vaccine is safe and how well it boosts immunity. If you are healthy and over 60, you might be able to join.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
Hear when a new Respiratory Syncytial Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.